NetworkNewsBreaks – AnPac Bio-Medical Science Co
Post# of 61
(Total Views: 259)
Posted On: 09/24/2021 3:40:13 PM
NetworkNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) CDA Technology Detects Risk of Over 25 Different Cancer Types
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a recognized innovator and leader in the field of early cancer screening and detection. Its core product and proven revenue generator, the pioneering Cancer Differentiation Analysis (“CDA”) platform, offers novel capabilities by looking for signals to help it assess the risk of cancer occurring before a tumor has developed. This approach is unlike the blood sample-based cancer screenings, which generally target protein-based biomarkers, genomic signals, such as circulating tumor DNA (“ct-DNA”), circulating in the bloodstream to determine if a cancer exists and is spreading. “In addition to CDA technology’s ability to detect early cancer risk, this technology has unique advantages in detecting multiple cancer types and is highly cost effective,” reads a recent article. “In 2015, the company performed its first commercial CDA-based test, with the capacity to screen for 16 different types of cancer using a multi-level, multi-parameter approach, well before its current competitors. The company now is able to detect the risk of 26 different cancer types with high sensitivity and specificity.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a recognized innovator and leader in the field of early cancer screening and detection. Its core product and proven revenue generator, the pioneering Cancer Differentiation Analysis (“CDA”) platform, offers novel capabilities by looking for signals to help it assess the risk of cancer occurring before a tumor has developed. This approach is unlike the blood sample-based cancer screenings, which generally target protein-based biomarkers, genomic signals, such as circulating tumor DNA (“ct-DNA”), circulating in the bloodstream to determine if a cancer exists and is spreading. “In addition to CDA technology’s ability to detect early cancer risk, this technology has unique advantages in detecting multiple cancer types and is highly cost effective,” reads a recent article. “In 2015, the company performed its first commercial CDA-based test, with the capacity to screen for 16 different types of cancer using a multi-level, multi-parameter approach, well before its current competitors. The company now is able to detect the risk of 26 different cancer types with high sensitivity and specificity.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)AnPac Bio-Medical Science Co. Ltd. (ANPC) Stock Research Links
Scroll down for more posts ▼